Mechanisms by which to reduce exposure to allogeneic blood are of financial and clinical
benefit in the hip fracture population. Tranexamic acid (TXA) is an inexpensive medication
with low complication risk. Its use in the hip fracture population is unproven. The purpose
of this study is to evaluate the efficacy and safety of topical tranexamic acid in reduction
of peri-operative blood loss in hip fracture surgery.